OncoHost to present proteomics-based predictive biomarker for immune-related adverse events in NSCLC Patients at SITC 2023

Original source here.

Novel computational model predicts significant irAEs in NSCLC patients based on proteomic profiling of one pre-treatment blood test.

OncoHost has developed a novel computational model for predicting significant immune-related adverse events (irAEs) in patients with non-small cell lung cancer (NSCLC) based on proteomic profiling of pre-treatment blood samples. The study was conducted using OncoHost’s PROphet platform and will be presented as a poster at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting.

OncoHost’s predictive model was developed on a cohort of 426 ICI-treated NSCLC patients taking part in the company’s ongoing, multicenter PROPHETIC clinical trial (NCT04056247). Plasma samples and clinical data, including irAE occurrence, were collected, and deep proteomic profiling was conducted using SomaLogic’s (NASDAQ: SLGC) SomaScan platform, measuring the expression levels of approximately 7,000 proteins.